BRPI0913379B8 - intermediário compactado compreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestão - Google Patents
intermediário compactado compreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestãoInfo
- Publication number
- BRPI0913379B8 BRPI0913379B8 BRPI0913379A BRPI0913379A BRPI0913379B8 BR PI0913379 B8 BRPI0913379 B8 BR PI0913379B8 BR PI0913379 A BRPI0913379 A BR PI0913379A BR PI0913379 A BRPI0913379 A BR PI0913379A BR PI0913379 B8 BRPI0913379 B8 BR PI0913379B8
- Authority
- BR
- Brazil
- Prior art keywords
- bibw
- compacted
- dimaleate
- powder
- solid oral
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- USNRYVNRPYXCSP-JUGPPOIOSA-N afatinib dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 USNRYVNRPYXCSP-JUGPPOIOSA-N 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000000843 powder Substances 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 3
- 230000037406 food intake Effects 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 abstract 7
- 239000013543 active substance Substances 0.000 abstract 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000007963 capsule composition Substances 0.000 abstract 1
- 238000005056 compaction Methods 0.000 abstract 1
- 238000007907 direct compression Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000007941 film coated tablet Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 239000007916 tablet composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
intermediário compactado compreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestão. a presente invenção refere-se a uma forma de dosagem farmacêutica contendo a substância ativa bibw 2992 como sal de dimaleato, provendo um perfil de liberação imediata da substância ativa, adicionalmente, a invenção se refere aos intermediários compactados compreendendo o sal de dimaleato bibw 2992 (bibw 2992 ma2) na forma de um pó preparado usando uma etapa de compactação e peneiração de rolo combinadas de bibw 2992 ma2, as misturas intermediárias preparadas do dito intermediário compactado assim como as formulações orais sólidas provendo um perfil de liberação imediata da substância ativa, feito a partir do dito intermediário compactado ou das misturas intermediárias prontas para o uso / ingestão, por exemplo cápsula e formulações de comprimidos tais como os comprimidos não revestidos ou revestidos por película preparados por compressão direta,e a métodos para sua produção.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08157800.7 | 2008-06-06 | ||
| EP08157800 | 2008-06-06 | ||
| EP09160297.9 | 2009-05-14 | ||
| EP09160297 | 2009-05-14 | ||
| PCT/EP2009/056944 WO2009147238A1 (en) | 2008-06-06 | 2009-06-05 | Solid pharmaceutical formulations comprising bibw 2992 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0913379A2 BRPI0913379A2 (pt) | 2015-11-24 |
| BRPI0913379B1 BRPI0913379B1 (pt) | 2020-03-31 |
| BRPI0913379B8 true BRPI0913379B8 (pt) | 2021-03-30 |
| BRPI0913379C1 BRPI0913379C1 (pt) | 2021-05-25 |
Family
ID=40941955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0913379A BRPI0913379C1 (pt) | 2008-06-06 | 2009-06-05 | intermediário compactado compreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestão |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8545884B2 (pt) |
| EP (1) | EP2299971B1 (pt) |
| JP (1) | JP5632367B2 (pt) |
| KR (1) | KR101641517B1 (pt) |
| CN (1) | CN102056589B (pt) |
| AR (1) | AR072062A1 (pt) |
| AU (1) | AU2009254574B2 (pt) |
| BR (1) | BRPI0913379C1 (pt) |
| CA (1) | CA2726472C (pt) |
| CL (1) | CL2010001275A1 (pt) |
| CO (1) | CO6280463A2 (pt) |
| CY (1) | CY1117895T1 (pt) |
| DK (1) | DK2299971T3 (pt) |
| EA (1) | EA022168B1 (pt) |
| EC (1) | ECSP10010650A (pt) |
| ES (1) | ES2588031T3 (pt) |
| HR (1) | HRP20161061T1 (pt) |
| HU (1) | HUE029863T2 (pt) |
| IL (1) | IL209054A (pt) |
| MA (1) | MA34030B1 (pt) |
| ME (1) | ME02478B (pt) |
| MX (1) | MX2010012939A (pt) |
| MY (1) | MY151240A (pt) |
| NZ (1) | NZ589568A (pt) |
| PE (1) | PE20100252A1 (pt) |
| PL (1) | PL2299971T3 (pt) |
| PT (1) | PT2299971T (pt) |
| RS (1) | RS54943B1 (pt) |
| SI (1) | SI2299971T1 (pt) |
| TW (1) | TWI453203B (pt) |
| UY (1) | UY31867A (pt) |
| WO (1) | WO2009147238A1 (pt) |
| ZA (1) | ZA201007805B (pt) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ516633A (en) | 1999-06-21 | 2004-09-24 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| DE10349113A1 (de) * | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| CA2629249C (en) * | 2005-11-11 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Combination treatment of cancer comprising egfr/her2 inhibitors |
| CA2833706C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| PL1981863T3 (pl) | 2006-01-26 | 2013-03-29 | Boehringer Ingelheim Int | Sposób wytwarzania pochodnych chinazoliny podstawionych przez ugrupowanie aminokrotonyloaminowe |
| CA2663599A1 (en) * | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
| PE20100252A1 (es) | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
| SI2451445T1 (sl) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino |
| US20120039999A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| US20130289056A1 (en) | 2010-08-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Methods of administering an egfr inhibitor |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| EP2951171A1 (en) | 2013-02-01 | 2015-12-09 | Boehringer Ingelheim International GmbH | Radiolabeled quinazoline derivatives |
| CN106279126B (zh) * | 2013-07-16 | 2019-05-24 | 杭州普晒医药科技有限公司 | 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物 |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| NO2699580T3 (pt) | 2014-01-24 | 2018-02-24 | ||
| CN105534920B (zh) * | 2014-10-29 | 2020-07-10 | 江苏豪森药业集团有限公司 | 一种药物组合物及其制备方法 |
| EP3023421A1 (en) | 2014-11-21 | 2016-05-25 | Sandoz Ag | Crystalline forms of afatinib dimaleate |
| CN105769804B (zh) * | 2014-12-23 | 2019-04-30 | 上海复星星泰医药科技有限公司 | 一种阿法替尼片及其制备方法 |
| CN105801568B (zh) | 2015-01-15 | 2019-07-30 | 杭州普晒医药科技有限公司 | 阿法替尼一马来酸盐晶型及其制备方法和药物组合物 |
| WO2016199076A2 (en) | 2015-06-12 | 2016-12-15 | Fresenius Kabi Oncology Ltd. | Polymorphic forms of afatinib free base and afatinib dimaleate |
| US10525059B2 (en) * | 2015-08-21 | 2020-01-07 | Fresenius Kabi Oncology, Ltd. | Pharmaceutical compositions comprising Afatinib |
| EP3156047A1 (en) | 2015-10-12 | 2017-04-19 | Sandoz Ag | Afatinib-containing formulation |
| CN105456222B (zh) * | 2015-12-22 | 2019-03-26 | 河南润弘制药股份有限公司 | 马来酸阿法替尼片及其制备方法 |
| EP3260114A1 (en) * | 2016-06-21 | 2017-12-27 | Omya International AG | Method for the production of a dosage form |
| EP3260115A1 (en) * | 2016-06-21 | 2017-12-27 | Omya International AG | Method for the production of a dosage form |
| CN106074427A (zh) * | 2016-07-31 | 2016-11-09 | 合肥远志医药科技开发有限公司 | 一种马来酸阿法替尼片剂及其制备方法 |
| BR112019010020A2 (pt) | 2016-11-17 | 2019-08-20 | Univ Texas | compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 |
| PL3573472T3 (pl) * | 2017-01-24 | 2025-02-24 | OmniGen Research, L.L.C. | Granulowany suplement paszowy oraz sposoby wytwarzania i zastosowania |
| EP3606916A1 (en) | 2017-04-06 | 2020-02-12 | Johnson Matthey Public Limited Company | Novel forms of afatinib dimaleate |
| WO2019070698A1 (en) | 2017-10-02 | 2019-04-11 | Johnson Matthey Public Limited Company | Novel forms of ibrutinib |
| PT3758708T (pt) * | 2018-03-01 | 2025-02-13 | Astrazeneca Ab | Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida |
| WO2019195827A1 (en) | 2018-04-06 | 2019-10-10 | Johnson Matthey Public Limited Company | Novel form of ibrutinib |
| WO2019209908A1 (en) | 2018-04-25 | 2019-10-31 | Johnson Matthey Public Limited Company | Crystalline forms of dasatinib |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| US12629375B2 (en) | 2019-03-29 | 2026-05-19 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions |
| JP2026503035A (ja) | 2023-01-06 | 2026-01-27 | インスメッド インコーポレイテッド | 新規な可逆性ｄｐｐ１阻害剤及びその用途 |
| WO2025162472A1 (en) | 2024-01-31 | 2025-08-07 | Insmed Incorporated | Linear dipeptidyl peptidase 1 inhibitors and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ516633A (en) | 1999-06-21 | 2004-09-24 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| US20030225079A1 (en) | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
| DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| CA2833706C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| CA2629249C (en) | 2005-11-11 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Combination treatment of cancer comprising egfr/her2 inhibitors |
| PL1981863T3 (pl) | 2006-01-26 | 2013-03-29 | Boehringer Ingelheim Int | Sposób wytwarzania pochodnych chinazoliny podstawionych przez ugrupowanie aminokrotonyloaminowe |
| US8338416B2 (en) * | 2006-03-16 | 2012-12-25 | Pharmacylics, Inc. | Indole derivatives as inhibitors of histone deacetylase |
| CA2663599A1 (en) | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
| PE20100252A1 (es) | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
| JP2012515184A (ja) | 2009-01-14 | 2012-07-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大腸がんの治療方法 |
| SI2451445T1 (sl) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino |
| WO2011069962A1 (en) | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Bibw 2992 for use in the treatment of triple negative breast cancer |
-
2009
- 2009-06-04 PE PE2009000775A patent/PE20100252A1/es active IP Right Grant
- 2009-06-04 UY UY0001031867A patent/UY31867A/es active IP Right Grant
- 2009-06-05 WO PCT/EP2009/056944 patent/WO2009147238A1/en not_active Ceased
- 2009-06-05 EA EA201001852A patent/EA022168B1/ru active Protection Beyond IP Right Term
- 2009-06-05 KR KR1020107027340A patent/KR101641517B1/ko active Active
- 2009-06-05 US US12/995,715 patent/US8545884B2/en active Active
- 2009-06-05 JP JP2011512146A patent/JP5632367B2/ja active Active
- 2009-06-05 NZ NZ589568A patent/NZ589568A/xx unknown
- 2009-06-05 SI SI200931496A patent/SI2299971T1/sl unknown
- 2009-06-05 HR HRP20161061TT patent/HRP20161061T1/hr unknown
- 2009-06-05 CA CA2726472A patent/CA2726472C/en active Active
- 2009-06-05 ME MEP-2016-138A patent/ME02478B/me unknown
- 2009-06-05 BR BRPI0913379A patent/BRPI0913379C1/pt active IP Right Grant
- 2009-06-05 PL PL09757619T patent/PL2299971T3/pl unknown
- 2009-06-05 HU HUE09757619A patent/HUE029863T2/en unknown
- 2009-06-05 PT PT97576193T patent/PT2299971T/pt unknown
- 2009-06-05 EP EP09757619.3A patent/EP2299971B1/en active Active
- 2009-06-05 CN CN2009801210803A patent/CN102056589B/zh active Active
- 2009-06-05 TW TW098118819A patent/TWI453203B/zh active
- 2009-06-05 DK DK09757619.3T patent/DK2299971T3/en active
- 2009-06-05 MA MA33400A patent/MA34030B1/fr unknown
- 2009-06-05 MX MX2010012939A patent/MX2010012939A/es active IP Right Grant
- 2009-06-05 ES ES09757619.3T patent/ES2588031T3/es active Active
- 2009-06-05 RS RS20160573A patent/RS54943B1/sr unknown
- 2009-06-05 AR ARP090102042A patent/AR072062A1/es unknown
- 2009-06-05 AU AU2009254574A patent/AU2009254574B2/en active Active
- 2009-06-05 MY MYPI20105644 patent/MY151240A/en unknown
-
2010
- 2010-11-01 ZA ZA2010/07805A patent/ZA201007805B/en unknown
- 2010-11-01 IL IL209054A patent/IL209054A/en active IP Right Grant
- 2010-11-19 CL CL2010001275A patent/CL2010001275A1/es unknown
- 2010-12-01 EC EC2010010650A patent/ECSP10010650A/es unknown
- 2010-12-03 CO CO10152537A patent/CO6280463A2/es not_active Application Discontinuation
-
2016
- 2016-08-10 CY CY20161100790T patent/CY1117895T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0913379C1 (pt) | intermediário compactado compreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestão | |
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| ECSP10010489A (es) | Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparación | |
| BRPI0922796A2 (pt) | Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo | |
| EA200901277A1 (ru) | Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина | |
| BR112012021681A2 (pt) | rifaximina em pó, processo para preparação da mesma e composições de liberação controladas contendo a referida rifaximina útil para obtenção de um efeito de longa duração. | |
| PE20100050A1 (es) | Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona | |
| CL2009000598A1 (es) | Composicion farmaceutica oral que comprende particulas de liberacion pulsatil controlada en el tiempo (tpr), que contienen un farmaco poco soluble debilmente basico y un acido organico separados por una capa de liberacion sostenida, y particulas de liberacion rapida (rr); capsula que la comprende; y su uso para tratar emesis. | |
| EA201190161A1 (ru) | Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения | |
| TNSN07337A1 (en) | Pharmaceutical composition comprising an indolylmaleimide derivative | |
| AR107391A1 (es) | Formulaciones / composiciones que comprenden un inhibidor de btk | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| EA201270573A1 (ru) | Гранулированный в расплаве цинакальцет | |
| UA112345C2 (uk) | Спосіб виготовлення за допомогою іонного желатинування інтестинальних альгінатних мікрокапсул, які містять диклофенак або одну із його солей, і багаточасткова фармацевтична композиція, що містить такі мікрокапсули | |
| BRPI0615195A8 (pt) | preparação farmacêutica, embalagem, e, métodos para tratar doença gastrintestinal, para fabricar uma cápsula e para testar dissolução de cápsulas de balsalazida. | |
| CL2008001325A1 (es) | Compuestos derivados de pirazol-piridinona; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar inflamacion, enfermedad de paget, osteoartritis, alzheimer, entre otras enfermedades. | |
| BRPI0514611A (pt) | uso de um composto, compostos, e, medicamento | |
| DK2091520T3 (da) | Oral doseringsform omfattende trisubstituerede glycerol-forbindelser | |
| UA102549C2 (ru) | Способ получения уплотненного промежуточного продукта дималеата bibw 2992, уплотненный промежуточный продукт и твердая пероральная таблетка | |
| MY158293A (en) | Pharmaceutical composition | |
| WO2016153222A3 (ko) | 텔미사르탄 칼륨염을 포함하는 약제학적 조성물 및 그 제조방법 | |
| EA201100679A1 (ru) | Покрытая пленочной оболочкой таблетка, содержащая иматиниб мезилат, способ ее получения и применение | |
| JP2013253026A (ja) | アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物 | |
| UY30697A1 (es) | Composicion farmacéutica solida de ibandronato, preparacion de la misma por compresion directa, formulacion farmacéutica conteniendo la misma y su preparacion. | |
| GR1007767B (el) | Φαρμακευτικο σκευασμα παρατεταμενης αποδεσμευσης περιεχον γκαλανταμινη και μεθοδος για την παρασκευη αυτου |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/03/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2569 DE 31/03/2020 QUANTO AO TITULO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |